Bank of New York Mellon
DMRA

Bank of New York Mellon’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Bank of New York Mellon’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.93M Buy
+151,016
New +$3.66M ﹤0.01% 2580

Other funds holding DMRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $29.3B AUM 38.15% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.9B AUM 37.22% 1-Year Est. Return
State Board of Administration of Florida Retirement System
State Board of Administration of Florida Retirement System Tallahassee, Florida $60.3B AUM 42.74% 1-Year Est. Return

Bank of New York Mellon's DMRA Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q2 2026: 151,016 shares worth $3.93M. The stake represents ﹤0.01% of the portfolio and ranks #2580 among its holdings.

20 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Bank of New York Mellon held 151,016 shares of Damora Therapeutics, Inc. Ordinary Shares worth $3.93M as of Q2 2026.
  • Damora Therapeutics, Inc. Ordinary Shares was a new Bank of New York Mellon position in Q2 2026.
  • Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2580 holding.
  • 20 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.